SCHEMBL20485742

SCHEMBL20485742

O=C(Cc1ccc(Cl)cc1)Nc1ccn(-c2ccccc2)n1

nearest known ligand 0.82

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ELOVL1 Q9BW60 3/20 0.82
▸ CACNA1G O43497 7/20 0.72
▸ CACNA1I Q9P0X4 7/20 0.72
▸ CACNA1H O95180 6/20 0.72
▸ LMNA P02545 2/20 0.68
▸ MAPT P10636 2/20 0.62
▸ KDM4E B2RXH2 1/20 0.60
▸ TSHR P16473 1/20 0.57
▸ HTT P42858 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ KMT2A Q03164 1/20 0.56
▸ CACNA1C Q13936 1/20 0.54
▸ TRPA1 O75762 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ NPC1 O15118 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ RAB9A P51151 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20249775 0.95 ELOVL1 (0.82) ELOVL1CACNA1GCACNA1ICACNA1HLMNA
SCHEMBL18320907 0.91 ELOVL1 (1.00) ELOVL1CACNA1GCACNA1ICACNA1HLMNA
SCHEMBL20485398 0.88 ELOVL1 (0.85) ELOVL1CACNA1GCACNA1ICACNA1HLMNA
SCHEMBL20249914 0.88 ELOVL1 (0.79) ELOVL1CACNA1GCACNA1ICACNA1HLMNA
SCHEMBL20485270 0.87 ELOVL1 (0.82) ELOVL1CACNA1GCACNA1ICACNA1HLMNA
SCHEMBL20250057 0.87 ELOVL1 (0.82) ELOVL1CACNA1GCACNA1ICACNA1HMAPT
SCHEMBL20485462 0.86 ELOVL1 (0.73) ELOVL1CACNA1GCACNA1ICACNA1HLMNA
SCHEMBL20485290 0.86 ELOVL1 (0.77) ELOVL1CACNA1GCACNA1ICACNA1HLMNA
SCHEMBL20485320 0.86 ELOVL1 (0.77) ELOVL1CACNA1GCACNA1ICACNA1HLMNA
SCHEMBL20485361 0.86 ELOVL1 (0.68) ELOVL1CACNA1GCACNA1ICACNA1HLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180251431-A1 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS VERTEX PHARMACEUTICALS INCORPORATED 2018-09-06 — — US claimed
US-20180251431-A1 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS VERTEX PHARMACEUTICALS INCORPORATED 2018-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180251431-A1 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS HSD17B4, CPT1A, ADH1A ELOVL1 39/4885CACNA1G 2851/4885CACNA1I 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback